PL2380587T3 - Zastosowanie inhibitora C1 do zapobiegania uszkodzeniu niedokrwiennoreperfuzyjnemu - Google Patents

Zastosowanie inhibitora C1 do zapobiegania uszkodzeniu niedokrwiennoreperfuzyjnemu

Info

Publication number: PL2380587T3
Authority: PL; Poland
Prior art keywords: inhibitor; ischemia; reperfusion injury; prevention; reperfusion
Prior art date: 2005-12-21

Application number

PL11172880T

Other languages

English (en)

Inventor

Maurice Mannesse

Johannes Henricus Nuijens

Frank Pieper

Simoni Maria Grazia De

Gijsbertus Johannes Ziere

Original Assignee

Pharming Intellectual Property B.V.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-12-21

Filing date

2006-12-19

Publication date

2018-03-30

2006-12-19 Application filed by Pharming Intellectual Property B.V. filed Critical Pharming Intellectual Property B.V.

2018-03-30 Publication of PL2380587T3 publication Critical patent/PL2380587T3/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Immunology (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Diabetes (AREA)
Vascular Medicine (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Surgery (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Peptides Or Proteins (AREA)

PL11172880T 2005-12-21 2006-12-19 Zastosowanie inhibitora C1 do zapobiegania uszkodzeniu niedokrwiennoreperfuzyjnemu PL2380587T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
EP05112630		2005-12-21
US76094406P	2006-01-23	2006-01-23
EP06824316A EP1965831B1 (en)	2005-12-21	2006-12-19	Use of c1 inhibitor for the prevention of ischemia-reperfusion injury
EP11172880.4A EP2380587B1 (en)	2005-12-21	2006-12-19	Use of C1 inhibitor for the prevention of ischemia-reperfusion injury

Publications (1)

Publication Number	Publication Date
PL2380587T3 true PL2380587T3 (pl)	2018-03-30

Family

ID=38016640

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL06824316T PL1965831T3 (pl)	2005-12-21	2006-12-19	Zastosowanie inhibitora C1 do profilaktyki uszkodzenia niedokrwienno-reperfuzyjnego
PL11172880T PL2380587T3 (pl)	2005-12-21	2006-12-19	Zastosowanie inhibitora C1 do zapobiegania uszkodzeniu niedokrwiennoreperfuzyjnemu

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL06824316T PL1965831T3 (pl)	2005-12-21	2006-12-19	Zastosowanie inhibitora C1 do profilaktyki uszkodzenia niedokrwienno-reperfuzyjnego

Country Status (15)

Country	Link
US (3)	US8071532B2 (pl)
EP (2)	EP2380587B1 (pl)
JP (2)	JP5394748B2 (pl)
KR (1)	KR101508668B1 (pl)
AT (1)	ATE516043T1 (pl)
AU (1)	AU2006327989B2 (pl)
CA (1)	CA2632400C (pl)
CY (2)	CY1112452T1 (pl)
DK (1)	DK2380587T3 (pl)
HR (2)	HRP20110622T1 (pl)
IL (2)	IL192180A (pl)
NZ (1)	NZ568749A (pl)
PL (2)	PL1965831T3 (pl)
SI (1)	SI2380587T1 (pl)
WO (1)	WO2007073186A2 (pl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2003301332B2 (en) *	2002-10-17	2008-06-12	Pharming Intellectual Property B.V.	Protein modification
EP2380587B1 (en)	2005-12-21	2017-10-25	Pharming Intellectual Property B.V.	Use of C1 inhibitor for the prevention of ischemia-reperfusion injury
JP2010505946A (ja) *	2006-10-10	2010-02-25	アカデミシュジーケンハウスビイデユニヴェアズィテートファンアムステルダム	神経再生改善のための補体阻害
JP5423266B2 (ja) *	2009-09-14	2014-02-19	富士電機株式会社	デジタル制御スイッチング電源装置
EP2497489A1 (en) *	2011-03-09	2012-09-12	CSL Behring GmbH	Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
WO2012120128A1 (en) *	2011-03-09	2012-09-13	Csl Behring Gmbh	Factor xii inhibitors for the administration with medical procedures comprising contact with artificial surfaces
CA2848510A1 (en) *	2011-09-24	2013-03-28	Csl Behring Gmbh	Combination therapy using immunoglobulin and c1-inhibitor
US10531655B2 (en)	2011-12-02	2020-01-14	The Regents Of The University Of California	Reperfusion protection solution and uses thereof
EP2793935B1 (en)	2011-12-22	2016-05-25	CSL Behring GmbH	Use of c1-inhibitor for the treatment of secondary edema of the central nervous system
WO2014008242A1 (en) *	2012-07-03	2014-01-09	The Trustees Of Columbia University In The City Of New York	The use of interleukin-11 to protect against ischemia and reperfusion injury
EP4613778A2 (en)	2012-10-25	2025-09-10	Bioverativ USA Inc.	Anti-complement c1s antibodies and uses thereof
EP2914291B1 (en)	2012-11-02	2022-02-23	Bioverativ USA Inc.	Anti-complement c1s antibodies and uses thereof
WO2014131865A1 (en) *	2013-02-28	2014-09-04	Csl Behring Gmbh	Therapeutic agent for amniotic fluid embolism
JP6636334B2 (ja) *	2013-03-08	2020-01-29	ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー	遠隔虚血再灌流傷害の治療および予防
MX389449B (es)	2013-03-15	2025-03-20	Viropharma Biologics Llc	Composiciones de inh-c1 y métodos para la prevención y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.
WO2014207199A1 (en)	2013-06-28	2014-12-31	Csl Behring Gmbh	Combination therapy using a factor xii inhibitor and a c1-inhibitor
JP6826040B2 (ja) *	2014-11-03	2021-02-03	スロンボリティック・サイエンス・リミテッド・ライアビリティ・カンパニーＴｈｒｏｍｂｏｌｙｔｉｃＳｃｉｅｎｃｅ，Ｌｌｃ	安全かつ効果的な血栓溶解（Ｔｈｒｏｍｂｏｌｙｓｉｓ）のための方法および組成物
CN117285634A (zh)	2015-04-06	2023-12-26	比奥贝拉蒂美国公司	人源化抗C1s抗体及其使用方法
EP3302529A4 (en)	2015-06-03	2019-02-06	The Children's Hospital Medical Center	COMPOSITIONS AND METHODS FOR TREATING GALLENA GANGATRESIA IN NEWBORNS
CA3005906A1 (en) *	2015-11-19	2017-05-26	Shire Human Genetic Therapies, Inc.	Recombinant human c1 esterase inhibitor and uses thereof
US20190175683A1 (en)	2016-08-05	2019-06-13	Csl Behring Gmbh	Pharmaceutical formulations of c1 esterase inhibitor
CA3034568A1 (en)	2016-08-23	2018-03-01	Csl Behring Gmbh	Method of preventing acute attacks of hereditary angioedema associated with c1 esterase inhibitor deficiency
TWI846007B (zh)	2016-10-12	2024-06-21	美商生物維瑞提夫美國公司	抗Ｃ１ｓ抗體及其使用方法
WO2018232305A1 (en)	2017-06-16	2018-12-20	Thrombolytic Science, Llc	Methods and compositions for thrombolysis
IL273185B2 (en)	2017-09-15	2024-10-01	Cedars Sinai Medical Center	C1 esterase inhibitors for use in improving organ function in organ transplantation subjects
WO2019166572A1 (en)	2018-02-28	2019-09-06	Pharming Intellectual Property B.V.	Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor
CA3092163A1 (en)	2018-02-28	2019-09-06	Pharming Intellectual Property B.V.	Treatment and prevention of pre-eclampsia
KR20210078527A (ko)	2018-10-17	2021-06-28	체에스엘 베링 게엠베하	C1-inh의 정제 방법
WO2021001525A1 (en)	2019-07-04	2021-01-07	Csl Behring Gmbh	Process for purifying c1-inh
KR102191500B1 (ko)	2020-03-30	2020-12-15	국립낙동강생물자원관	초석잠 추출물을 포함하는 기억력 및 인지기능 개선, 허혈 재관류 손상 예방 및 개선용 조성물
EP3895726A1 (en)	2020-04-17	2021-10-20	Pharming Intellectual Property BV	Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress
KR102217607B1 (ko)	2020-06-01	2021-02-18	국립낙동강생물자원관	석창포 추출물을 포함하는 기억력 및 인지기능 개선, 허혈 재관류 손상 예방 및 개선용 조성물
KR102191452B1 (ko)	2020-06-30	2020-12-15	주식회사 에이치비헬스케어	곶감 추출물을 포함하는 기억력 및 인지기능 개선, 허혈 재관류 손상 예방 및 개선용 조성물
JP2023551193A (ja)	2020-11-20	2023-12-07	ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー	抗体関連型拒絶反応を処置するための方法
CA3225079A1 (en)	2021-07-09	2023-01-12	Bruno Giannetti	Using c1 esterase inhibitor to treat viral infection-related symptoms

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6562784B1 (en)	1999-05-14	2003-05-13	Steffen Thiel	Indications of mannan-binding lectin (MBL) in the treatment of immunocompromised individuals
WO2001057079A2 (en) *	2000-01-31	2001-08-09	Pharming Intellectual Property B.V.	C1 inhibitor produced in the milk of transgenic mammals
US7067713B2 (en)	2000-01-31	2006-06-27	Pharming Intellectual Property B.V.	C1 Inhibitor produced in the milk of transgenic non-human mammals
JP2004100982A (ja) *	2002-09-05	2004-04-02	Denso Corp	熱交換器
AU2003301332B2 (en)	2002-10-17	2008-06-12	Pharming Intellectual Property B.V.	Protein modification
AU2004238170B2 (en)	2003-05-16	2009-11-05	Pharming Intellectual Property B.V.	C1 inhibitor with short half-life for transient treatment
EP2380587B1 (en)	2005-12-21	2017-10-25	Pharming Intellectual Property B.V.	Use of C1 inhibitor for the prevention of ischemia-reperfusion injury

2006
- 2006-12-19 EP EP11172880.4A patent/EP2380587B1/en active Active
- 2006-12-19 JP JP2008547134A patent/JP5394748B2/ja not_active Expired - Fee Related
- 2006-12-19 PL PL06824316T patent/PL1965831T3/pl unknown
- 2006-12-19 CA CA2632400A patent/CA2632400C/en active Active
- 2006-12-19 AT AT06824316T patent/ATE516043T1/de active
- 2006-12-19 WO PCT/NL2006/050321 patent/WO2007073186A2/en not_active Ceased
- 2006-12-19 HR HR20110622T patent/HRP20110622T1/hr unknown
- 2006-12-19 KR KR1020087017880A patent/KR101508668B1/ko active Active
- 2006-12-19 NZ NZ568749A patent/NZ568749A/en unknown
- 2006-12-19 EP EP06824316A patent/EP1965831B1/en active Active
- 2006-12-19 US US12/158,987 patent/US8071532B2/en active Active
- 2006-12-19 SI SI200632219T patent/SI2380587T1/en unknown
- 2006-12-19 DK DK11172880.4T patent/DK2380587T3/en active
- 2006-12-19 AU AU2006327989A patent/AU2006327989B2/en active Active
- 2006-12-19 PL PL11172880T patent/PL2380587T3/pl unknown
2008
- 2008-06-15 IL IL192180A patent/IL192180A/en active IP Right Grant
2011
- 2011-10-05 CY CY20111100950T patent/CY1112452T1/el unknown
- 2011-10-11 US US13/271,107 patent/US8415288B2/en active Active
2013
- 2013-02-04 JP JP2013019186A patent/JP2013126992A/ja active Pending
- 2013-02-25 US US13/776,529 patent/US9211318B2/en active Active
- 2013-10-17 IL IL228954A patent/IL228954A/en active IP Right Grant
2017
- 2017-11-13 HR HRP20171738TT patent/HRP20171738T1/hr unknown
2018
- 2018-01-10 CY CY20181100029T patent/CY1119818T1/el unknown

Also Published As

Publication number	Publication date
EP2380587B1 (en)	2017-10-25
IL228954A (en)	2016-10-31
JP2009520815A (ja)	2009-05-28
US20130244941A1 (en)	2013-09-19
US20120088728A1 (en)	2012-04-12
SI2380587T1 (en)	2018-03-30
CA2632400C (en)	2016-06-07
CA2632400A1 (en)	2007-06-28
PL1965831T3 (pl)	2011-12-30
IL192180A0 (en)	2009-02-11
EP1965831A2 (en)	2008-09-10
KR20080098001A (ko)	2008-11-06
US8415288B2 (en)	2013-04-09
EP1965831B1 (en)	2011-07-13
CY1119818T1 (el)	2018-06-27
HRP20171738T1 (hr)	2018-01-26
KR101508668B1 (ko)	2015-04-06
EP2380587A1 (en)	2011-10-26
HRP20110622T1 (hr)	2011-09-30
AU2006327989B2 (en)	2012-06-07
IL228954A0 (en)	2013-12-31
US20080305993A1 (en)	2008-12-11
US8071532B2 (en)	2011-12-06
IL192180A (en)	2013-10-31
DK2380587T3 (en)	2017-12-04
WO2007073186A3 (en)	2007-08-09
JP5394748B2 (ja)	2014-01-22
JP2013126992A (ja)	2013-06-27
NZ568749A (en)	2011-05-27
ATE516043T1 (de)	2011-07-15
CY1112452T1 (el)	2015-12-09
AU2006327989A1 (en)	2007-06-28
WO2007073186A2 (en)	2007-06-28
US9211318B2 (en)	2015-12-15

Publication	Publication Date	Title
IL228954A0 (en)	2013-12-31	Use of C1 inhibitors for the prevention of ischemia-reperfusion injuries
MX2007007409A (es)	2007-07-12	Derivados de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos.
MX2009008338A (es)	2009-08-12	Compuestos de piridopirimidinona de utilidad en el tratamiento de enfermedades o condiciones patologicas mediadas por los canales de sodio.
IL191629A0 (en)	2008-12-29	Tricyclic amide derivatives useful for treating obesity
IL189694A0 (en)	2008-06-05	Biphenyl derivatives and their use in treating hepatitis c
UA101943C2 (ru)	2013-05-27	Биарилзамещенные гетероциклические ингибиторы lta4h для лечения воспаления
JO2372B1 (en)	2006-12-12	Source drugs of 4-phenylpyridine derivatives
GB0225475D0 (en)	2002-12-11	Therapeutic agents
PL367527A1 (pl)	2005-02-21	Fluoropirolidyny jako inhibitory peptydazy dipeptydylowej
UA92355C2 (en)	2010-10-25	urn:schemas-microsoft-com:office:smarttags2,4-DIAMINO-PYRIMIDINES USED AS AURORAINHIBITORS
WO2007136603A3 (en)	2008-01-17	Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2003002530A3 (en)	2003-04-03	Pyrrolidines as dipeptidyl peptidase inhibitors
IL183514A0 (en)	2007-09-20	Pyrrolidine inhibitors of iap
WO2008151288A3 (en)	2009-09-24	Aromatic and heteroaromatic compounds useful in treating iron disorders
ZA200806778B (en)	2009-11-25	N-Hydroxyacrylamide compounds
MX2009010083A (es)	2009-10-12	Compuestos biarilo y biheteroarilo de utilidad en el tratamiento de trastornos de hierro.
UA87843C2 (ru)	2009-08-25	Применение пептидных соединений для лечения расстройств функционирования мотонейронов или/и периферических невропатий
SI1855677T1 (sl)	2009-04-30	3,11 b-cis-dihidrotetrabenazin za zdravljenje shizofrenije in drugih psihoz
UA88166C2 (ru)	2009-09-25	Применение пептидных соединений для лечения эссенцильного дрожания и других синдромов дрожания
WO2006079547A3 (en)	2006-09-21	Spm 927 for add-on therapy of schizophrenia
PL1919466T3 (pl)	2012-05-31	Formulacje do leczenia nieprawidłowości lipoproteinowych obejmujące statynę i pochodną metylonikotynoamidu
MY145823A (en)	2012-04-30	Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
EP2036555A4 (en)	2009-11-11	USE OF PYRIDONE DERIVATIVES FOR THE PREVENTION AND TREATMENT OF RADIOACTIVE LUNG INJURY
WO2009148600A8 (en)	2010-02-25	Deuterated lysine-based compounds
TW200738643A (en)	2007-10-16	Cyclourea compounds and the use thereof